|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0022671,
umls-concept:C0030705,
umls-concept:C0032105,
umls-concept:C0041004,
umls-concept:C0086045,
umls-concept:C0547047,
umls-concept:C0678226,
umls-concept:C0683150,
umls-concept:C0702240,
umls-concept:C1149837
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-7-8
|
|
pubmed:abstractText |
Hyperlipidemia is a frequent and persistent complication in solid organ transplant recipients, leading to the high occurrence of cardiovascular disease in this patient population. Lipid abnormalities including increased total cholesterol, triglycerides (TG), and low-density lipoprotein-cholesterol have been reported frequently in transplantation patients and a variety of immunosuppressive therapies seem to be one of the main factors that influence posttransplant lipidemic profiles. For many years, tacrolimus (TAC) has been used as an immunosuppressive drug in transplantation. The aim of our investigation was to determine the effect of TAC administration on the plasma lipid profile and some key regulatory proteins of plasma lipid metabolism including cholesterol ester transfer protein, hepatic lipase and lipoprotein lipase (LPL) within renal transplant patients.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CETP protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol,
http://linkedlifedata.com/resource/pubmed/chemical/Cholesterol Ester Transfer Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxymethylglutaryl-CoA...,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Lipase,
http://linkedlifedata.com/resource/pubmed/chemical/Lipoprotein Lipase,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/Triglycerides,
http://linkedlifedata.com/resource/pubmed/chemical/hepatic lipase, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1534-6080
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
62-8
|
|
pubmed:meshHeading |
pubmed-meshheading:19584682-Adult,
pubmed-meshheading:19584682-Aged,
pubmed-meshheading:19584682-Cholesterol,
pubmed-meshheading:19584682-Cholesterol Ester Transfer Proteins,
pubmed-meshheading:19584682-Down-Regulation,
pubmed-meshheading:19584682-Drug Monitoring,
pubmed-meshheading:19584682-Drug Therapy, Combination,
pubmed-meshheading:19584682-Female,
pubmed-meshheading:19584682-Humans,
pubmed-meshheading:19584682-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:19584682-Hypertriglyceridemia,
pubmed-meshheading:19584682-Immunosuppressive Agents,
pubmed-meshheading:19584682-Kidney Transplantation,
pubmed-meshheading:19584682-Lipase,
pubmed-meshheading:19584682-Lipoprotein Lipase,
pubmed-meshheading:19584682-Male,
pubmed-meshheading:19584682-Middle Aged,
pubmed-meshheading:19584682-Tacrolimus,
pubmed-meshheading:19584682-Time Factors,
pubmed-meshheading:19584682-Triglycerides
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Tacrolimus-induced elevation in plasma triglyceride concentrations after administration to renal transplant patients is partially due to a decrease in lipoprotein lipase activity and plasma concentrations.
|
|
pubmed:affiliation |
Faculty of Medicine, Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
